TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06619587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase I Arm A
Description: Dose escalation and expansion arm, with protocol-defined dose(s) of GDC-7035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase I Arm B
Description: Dose escalation and expansion arm, with protocol-defined dose(s) of GDC-7035 in combination with other anti-cancer therapies
Study: NCT06625957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTCB02-1
Description: 3 Days infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NTCB-C
Description: 3 Days infusion
Study: NCT06630780

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Head and Neck Cancers
Description: All patients received intensity-modulated conformal radiotherapy (IMRT). To ensure study quality, all IMRT plans were reviewed by the research team at Sun Yat-sen University Cancer Center. The delineation principles for the radiotherapy target volume of the primary tumor bed and normal tissues followed the consensus guidelines.
Study: NCT06700733

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEEK prosthesis
Description: For the PP, The PEEK framework will be constructed, the fit of the PEEK framework will be verified intraorally, and the final screw-retained prosthesis will be constructed of PMMA teeth and a visiolign pink composite estimating the gingival tissue.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEEK prosthesis
Description: For the PP, The PEEK framework will be constructed, the fit of the PEEK framework will be verified intraorally, and the final screw-retained prosthesis will be constructed of PMMA teeth and a visiolign pink composite estimating the gingival tissue.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Titanium prosthesis
Description: For the TP, the framework will be milled from Ti blocks according to the virtual design of the final prosthesis framework. PMMA teeth then will be cemented, and the final prosthesis will be screwed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Titanium prosthesis
Description: For the TP, the framework will be milled from Ti blocks according to the virtual design of the final prosthesis framework. PMMA teeth then will be cemented, and the final prosthesis will be screwed.
Study: NCT06706661

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional treatment
Description: At day 4 after discharge, the intervention group (IG) receives dietetic counselling including a recommendation of daily training, an individual nutrition plan and a package containing foods and drinks covering dietary requirements for the next 24 h. Further, a goodie-bag containing samples of protein-rich milk-based drinks is provided.~Information regarding recommendations of nutritional therapy after discharge is systematically and electronically communicated to the municipality. The dietician performes telephone follow-ups on day 30 and a home visit at 12 weeks
Study: NCT06715241

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: combination of relatlimab and nivolumab wich are two immunotherapy treatments
Description: Induction: Nivolumab 360 mg/relatlimab 360 mg fixed dose combination, IV, 6 weeks Off treatment period: 4 to 6 weeks Maintenance: Nivolumab 480 mg/relatlimab 480 mg fixed dose combination, IV 13 cycles (Q4W): 52 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Nivolumab alone
Description: Induction: Nivolumab alone 360 mg, IV2 cycles (Q3W): 6 weeks Off treatment period: 4 to 6 weeks Maintenance: Nivolumab alone 480 mg, IV, 13 cycles (Q4W): 52 weeks
Study: NCT06749756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin B6+ Vitamin B12 +vitamin C
Description: In addition to the basic treatment of sepsis, intravenous injection of vitamin B6 300mg qd Vitamin B12 0.5mg q6h, vitamin C 50mg/kg q6h for 4 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin B6+ Vitamin B12
Description: In addition to the basic treatment of sepsis, vitamin B6 300mg qd and vitamin B12 0.5mg q6h were given intravenously for 4 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin C
Description: On the basis of the basic treatment of sepsis, intravenous vitamin C 50mg/kg q6h was given for 4 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9%Nacl
Description: The same dose of placebo (0.9% sodium chloride solution) was administered on top of the sepsis base treatment for 4 days.
Study: NCT06758037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug therapy
Description: All patients will receive one cycle of HiR (Zebtorizumab, Lenalidomide) induction therapy. On the first day of enrollment, tissue NGS and peripheral blood ctDNA will be submitted for testing. For the remaining six cycles, the added drug (X) will be determined based on the NGS molecular typing results. Please refer to the grouping scheme for details.~HiR+X Dosing Scheme:~Hi: Zebtorizumab 375mg/m², d1; R: Lenalidomide 10-25mg d1-10 (maximum tolerated dose)~X:~For MCD/BN2/TP53: Ocalivumab 150mg qd For EZB: Chidamide 30mg biw~For N1-like and nonspecific types:~If EBV-positive: PD-1 monoclonal antibody 200mg Q3W
Study: NCT06757751

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EVOO diet supplement
Description: For 24 weeks, subjects in intervention arm will have their diet supplemented, daily, with an amount of 30 ml of EVOO (Extra Virgin Olive Oil).
Study: NCT06760078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous tranexamic acid (TXA) infusion
Description: Intravenous tranexamic acid will be administered as an initial dose of 1 g (10mL: 1g, diluted in 90 mL normal saline) over 10 minutes, followed by a maintenance dose of 1 g over 8 hours (10mL: 1g, diluted in 240 mL normal saline). Intensive blood pressure lowering will be maintained throughout the treatment period until 24 hours after onset.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An intravenous placebo (10mL NS, diluted in 90mL NS) matching the specification and appearance of TXA will be administered as an initial bolus over 10 minutes, followed by a continuous infusion of placebo (10mL NS, diluted in 240mL NS) over 8 hours, with intensive blood pressure lowering maintained throughout the treatment period and continued until 24 hours after symptoms onset.
Study: NCT06762431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Dose Level 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Dose Level 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Dose Level 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Dose Level 2
Study: NCT06760676

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pulsed low dose rate radiotherapy (PLDR)
Description: Radiation 5 times per week, 2Gy each time which divided into 10 pulse doses, each pulse interval was 3 minutes, the dose rate was 0.067 Gy/min, and each treatment time was 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpaloritovorelli antibodies
Description: PLDR external irradiation therapy was administered simultaneously with 5mg/kg Alpaloritovorelli antibodies for a 3-week regimen, the following maintenance treatment was 2 years.
Study: NCT06761638

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Rhythmic Auditory Stimulation Therapy
Description: Rhythmic auditory stimulation (RAS) is a therapeutic technique that uses rhythmic auditory cues, like a metronome or music, to improve motor control and coordination. It is often used in rehabilitation for conditions such as stroke, Parkinson's disease, and other movement disorders to enhance gait and other motor functions through the synchronization of movements to auditory rhythms.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Task-Specific Training
Description: Task-specific training is a rehabilitation approach that involves practicing specific tasks or activities to improve the performance of those tasks. It is based on the principle that repetitive practice of functional tasks enhances neuroplasticity, leading to better motor skills and functional recovery, especially in stroke and neurological rehabilitation.
Study: NCT06761755

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hot pack , K taping , Progressive muscle relaxation
Description: Group A has given the kinesiology taping on the lower abdomen and back for 1-3 days with progressive muscle relaxation technique for 10-20 minutes and a baseline treatment hot pack at a time twice a day from the start of menstruation~Group B has receive the kinesiology taping on the lower abdomen and baseline treatment hot pack without progressive muscle relaxation technique for 1-3 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hot pack , K taping , Progressive muscle relaxation
Description: Group A has given the kinesiology taping on the lower abdomen and back for 1-3 days with progressive muscle relaxation technique for 10-20 minutes and a baseline treatment hot pack at a time twice a day from the start of menstruation~Group B has receive the kinesiology taping on the lower abdomen and baseline treatment hot pack without progressive muscle relaxation technique for 1-3 days
Study: NCT06762080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab (AK104)
Description: Intrathecal injection of 62.5 mg PD-1/CTLA-4 bispecific antibody was administered every two weeks for six weeks during the induction phase, followed by monthly injections during the maintenance phase, until recurrence or death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed (Alimta)
Description: Pemetrexed intrathecal chemotherapy is administered by intracerebroventricular or lumbar puncture. Pemetrexed intrathecal chemotherapy is divided into induction, consolidation and maintenance phases. Induction therapy was first performed with a single dose of 15 mg twice a week for 2 weeks for a total of 4 doses. This was followed by consolidation therapy, 1 time per week for 4 consecutive weeks for a total of 4 times.
Study: NCT06761482

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: monitoring by dd-cfDNA
Description: monitoring by dd-cfDNA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: monitoring by T-Vis
Description: monitoring by T-Vis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: monitoring by dd-cfDNA+ T-Vis
Description: monitoring by dd-cfDNA+ T-Vis
Study: NCT06761235

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Standard BP intervention
Description: Behavioral: lifestyle counseling will be given according to international guidelines to reduce blood pressure.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EVA intervention
Description: Behavioral: lifestyle counseling will be given according to international guidelines to reduce blood pressure. In contrast to BP arm, EVA arm will additionally reciuve counseling about vascular age.
Study: NCT06761508

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intervention study for Arm one using video
Description: A 3 Arm randomized control trial, using video as the first Arm of intervention to assess the behaviour change of the community in hypertension prevention.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: intervention 2:using infographics
Description: A 3 Arm randomized control trial,that involves the use of infographics in Arm to assess the behaviour change of the community in hypertension prevention.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: intervention 3: use of pamphlet
Description: A 3 Arm randomized control trial,that contains the use of pamphlet for the 3rd Arm which is the control group to assess the behaviour change of the community in hypertension prevention.
Study: NCT06761378

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Renal stent
Description: Renal stent before flexible uretroscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Renal stent
Description: Renal stent before flexible uretroscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible uretroscopy
Description: Renal stent for 2 weeks prior flexible uretroscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible uretroscopy
Description: Renal stent for 2 weeks prior flexible uretroscopy
Study: NCT06762405

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: short course of radiotherapy (5 grays × 5 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dostarlimab
Description: dostarlimab 500 mg intravenous infusion every 3 weeks for 6 months (nine cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: dostarlimab 500 mg intravenous infusion every 3 weeks for 6 months (nine cycles)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Biological study on circulating tumor DNA (optional for the patient)
Description: * Tissue collection (3 time points: baseline, w12 and 25) for:~* Exome (on tumor and normal tissue),~* 3'RNAseq,~* Hiplex Immunofluorescence~* In addition, 48 patients will be tested for Spatial transcriptomics assuming that 24 patients may have non-complete response and/or local recurrence and/or metastatic recurrence and will be paired with 24 patients with complete response and free of any disease at 2 years.~* Blood collection (5 time points: baseline, w3, 6, 12 and 24) for:~* ctDNA~* Cytokine dosage~* Proteomic analyses~* Stool collection (3 time points: baseline, w3 and 24) for:~Microbiota analyses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological study on circulating tumor DNA (optional for the patient)
Description: * Tissue collection (3 time points: baseline, w12 and 25) for:~* Exome (on tumor and normal tissue),~* 3'RNAseq,~* Hiplex Immunofluorescence~* In addition, 48 patients will be tested for Spatial transcriptomics assuming that 24 patients may have non-complete response and/or local recurrence and/or metastatic recurrence and will be paired with 24 patients with complete response and free of any disease at 2 years.~* Blood collection (5 time points: baseline, w3, 6, 12 and 24) for:~* ctDNA~* Cytokine dosage~* Proteomic analyses~* Stool collection (3 time points: baseline, w3 and 24) for:~Microbiota analyses
Study: NCT06761898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-43395
Description: Administered orally as solid dispersion tablet or salt tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-43395
Description: Administered orally as solid dispersion tablet or salt tablet
Study: NCT06760897

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gastrogenic Microbiota
Description: Take 1 sachet of gastric-origin probiotic powder (containing 5 x 1011 CFU per sachet) twice daily for 8 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: similar powder administered twice daily
Study: NCT06761209

Intervention type: OTHER
Intervention: blood sampling
Description: For the study, a blood sample will be collected from the patient in order to do build up a serological library which will allow the search for rare autoAb whose interest has been demonstrated as prognostic factors of the disease.
Study: NCT06761677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brincidofovir
Description: Phase 1b part is dose escalation study evaluating three dose levels of BCV, and participants will be assigned to a dose schedule in the order of study entry. In Phase 2 part, participants will receive BCV BIW at the RP2D (determined in the Phase 1b part).
Study: NCT06760546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: Solution for daily subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to setmelanotide for daily subcutaneous injection
Study: NCT06762158

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemoradiotherapy
Description: Neoadjuvant chemoradiotherapy:~1. Radiation dose: 1.8Gy/Fx, DT41.4Gy/23Fx.~2. Concurrent chemotherapy: Albumin-bound paclitaxel 60mg/m² + Cisplatin 25mg/m² on D1, D8, D15, D22, D29.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant immunotherapy
Description: Begins on the second day after the completion of concurrent chemoradiotherapy, and no later than one week. Toripalimab 240mg Q3W, for a total of two cycles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Preoperative assessment is conducted 3 weeks after the last neoadjuvant immunotherapy, and surgery is performed within 4-6 weeks. All patients undergo minimally invasive radical esophagectomy, either McKeown or Ivor-Lewis, with extended two-field or three-field lymph node dissection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjuvant immunotherapy
Description: Whether to undergo postoperative adjuvant immunotherapy is determined based on the pathological response. Patients with pCR are only observed without receiving adjuvant treatment, while those not reaching pCR receive one year of adjuvant Toripalimab.
Study: NCT06760949

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct anterior approach hemiarthroplasty
Description: Direct anterior approach hemiarthroplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior lateral approach hemiarthroplasty
Description: Posterior lateral approach hemiarthroplasty
Study: NCT06762587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baloxavir Marboxil
Description: Baloxavir marboxil will be administered on the first day following the close contact's enrollment in this study. Participants weighing ≤80 kg will receive 40 mg of baloxavir marboxil, while those weighing ≥80 kg will receive 80 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oseltamivir will be administered once daily for 5 consecutive days following the close contact's enrollment in this study. Participants will receive 75 mg of oseltamivir once each day.
Study: NCT06762197

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Physical therapy can be beneficial for patients with piriformis syndrome, including stretching exercises, local massage, and superficial heat. Traditional stretching techniques include external rotation, hip flexion, and adduction. A hot pack on the trigger point area for 10 minutes followed by passive stretching for 30 seconds each.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Physical therapy can be beneficial for patients with piriformis syndrome, including stretching exercises, local massage, and superficial heat. Traditional stretching techniques include external rotation, hip flexion, and adduction. A hot pack on the trigger point area for 10 minutes followed by passive stretching for 30 seconds each.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Physical therapy can be beneficial for patients with piriformis syndrome, including stretching exercises, local massage, and superficial heat. Traditional stretching techniques include external rotation, hip flexion, and adduction. A hot pack on the trigger point area for 10 minutes followed by passive stretching for 30 seconds each.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: shockwave therapy
Description: Shockwave therapy is a non-invasive alternative treatment for muscle disorders like sports and traumatic injuries, as it reduces pain and promotes soft tissue repair. In a study, patients in group A were treated with three sessions of Storz Medical Shock Wave MP100, each consisting of 2000 pulses with a total energy dose of 1080 mJ / mm. The study aimed to determine the location of the piriformis muscle in the prone position.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low level laser therapy
Description: Low Level Laser Therapy, also known as Photo-biomodulation, is a low-intensity light therapy that triggers biochemical changes within cells, similar to photosynthesis in plants. It can treat nociceptive and neuropathic pain, but central pain has not been proven responsive to low level laser therapy.
Study: NCT06761547

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: magnsium sulfate
Description: patients will take magnsium sulfate 15 mg/kg IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine (drug)
Description: patients will take lidocaine2% 1 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: 50 ml saline IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: 50 ml saline IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 50 ml saline IV
Study: NCT06761053

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Intervention/Exposure for the GDM Group (Experimental Arm)
Description: Gestational Diabetes Diagnosis: The intervention for this group involves the diagnostic procedure of the 100-gram oral glucose tolerance test (OGTT) after an initial glucose challenge test (GCT) with a result equal to or greater than 140 mg/dL. The test assesses fasting plasma glucose and post-glucose consumption plasma glucose levels at 1 hour and 2 hours, which is used to diagnose GDM.~Biomarker Analysis: The albumin to high-sensitivity C-reactive protein (hsCRP) ratio is measured as a biomarker to explore its potential role in GDM diagnosis and related pregnancy outcomes.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Intervention/Exposure for the Control Group
Description: Glucose Challenge Test (GCT): The control group participants are exposed to the glucose challenge test (GCT), where plasma glucose levels are measured one hour after the consumption of 50 grams of glucose. If their glucose levels are below 140 mg/dL, they are categorized as not having GDM.~Biomarker Analysis: Similar to the GDM group, the albumin to hsCRP ratio is measured for participants in the control group to compare the biomarker levels between those with and without GDM.
Study: NCT06761274

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: peripheral blood sampling
Description: It is a monocentric and exploratory study, experimental on human tissues in vitro and similar projects do not exist in the literature. This study involves the analysis of peripheral blood in patients with hodgkin lymphoma with the following characteristics:~* in complete remission for at least two years after first-line therapy with stage II b, III or IV at onset (Ann Arbor classification).~* newly diagnosed (stage II b, III or IV, Ann Arbor Classification).